Te impact of the national HPV vaccination program in England using the bivalent HPV vaccine: Surveillance of type-specifc HPV in young females, 2010-2016

Journal of Infectious Diseases

Volumn 218, Issue 6, 2018, Pages 911-921

  Mesher, David ^a,c,d   Panwar, Kavita ^b   Thomas, Sara L ^d   Edmundson, Claire ^a   Choi, Yoon Hong ^c   Beddows, Simon ^b   Soldan, Kate ^a  

^a Public Health England   (United Kingdom)

^b Virus Reference Department Public Health England   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Bivalent; HPV vaccine; Human papillomavirus; Prevalence; Vaccine eflectiveness; Vaccine impact

Indexed keywords

WART VIRUS VACCINE; VIRUS DNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; DISEASE SURVEILLANCE; DRUG EFFICACY; ENGLAND; FEMALE; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; INFECTION RATE; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; MATHEMATICAL MODEL; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROGRAM IMPACT; VACCINATION COVERAGE; VAGINA SMEAR; YOUNG ADULT; CLASSIFICATION; GENETICS; HEALTH SURVEY; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PROGRAM EVALUATION; VIROLOGY;

ADOLESCENT; AGE DISTRIBUTION; DNA, VIRAL; ENGLAND; FEMALE; HUMANS; MASS VACCINATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; PROGRAM EVALUATION; YOUNG ADULT;

EID: 85053211476     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy249     Document Type: Article

References (24)

1. Schifman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016; 2:16086.
2. Paavonen J, Jenkins D, Bosch FX, et al.; HPV PATRICIA study group. Efcacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70.
3. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013; 10:400-10.
4. de Sanjose S, Quint WG, Alemany L, et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56.
5. Mesher D, Cuschieri K, Hibbitts S, et al. Type-specifc HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the efects of immunisation. J Clin Pathol 2015; 68:135-40.
6. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
7. Garland SM, Hernandez-Avila M, Wheeler CM, et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
8. Hawkins MG, Winder DM, Ball SL, et al. Detection of spe-cifc HPV subtypes responsible for the pathogenesis of con-dylomata acuminata. Virol J 2013; 10:137.
9. Public Health England. Human Papillomavirus (HPV) Vaccine Coverage in England, 2008/09 to 2013/14. A review of the full six years of the three-dose schedule. https://www.gov.uk/government/uploads/system/uploads/attachment-data/fle/412264/HPV-Vaccine-Coverage-in- England-200809-to-201314.pdf. Accessed May 2016.
10. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd efects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80.
11. Mesher D, Soldan K, Lehtinen M, et al. Population-level efects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis 2016; 22:1732-40.
12. Mesher D, Panwar K, Tomas SL, Beddows S, Soldan K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open 2016; 6:e009915.
13. Howell-Jones R, de Silva N, Akpan M, et al. Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine 2012; 30:3867-75.
14. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013; 32:26-32.
15. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010; 28:4091-102.
16. Bissett SL, Howell-Jones R, Swif C, et al. Human papillo-mavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol 2011; 83:1744-51.
17. Malagón T, Drolet M, Boily MC, et al. Cross-protective ef-cacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-9.
18. Wheeler CM, Castellsagué X, Garland SM, et al.; HPV PATRICIA Study Group. Cross-protective efcacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, dou-ble-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10.
19. Bouvard V, Baan R, Straif K, et al.; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10:321-2.
20. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017; 17:1293-302.
21. Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females afer vaccine introduction-national health and nutrition examination survey, United States, 2003-2014. J Infect Dis 2017; 216:594-603.
22. Baussano I, Lazzarato F, Ronco G, Lehtinen M, Dillner J, Franceschi S. Diferent challenges in eliminating HPV16 compared to other types: a modeling study. J Infect Dis 2017; 216:336-44.
23. Söderlund-Strand A, Uhnoo I, Dillner J. Change in population prevalences of human papillomavirus afer initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev 2014; 23:2757-64.
24. Woestenberg PJ, King AJ, van Benthem BHB, et al.; Medical Microbiological Laboratories and the Public Health Services. Bivalent vaccine efectiveness against type-specifc HPV pos-itivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors. J Infect Dis 2018; 217:213-22.